Continuous Glucose Monitoring for Gestational Diabetes

(POSTPOD Trial)

This trial explores how using a continuous glucose monitor (CGM) immediately after childbirth can help predict the risk of developing Type 2 Diabetes in those who had gestational diabetes. Participants will wear the CGM device for 24 hours to track blood sugar levels. Individuals who received prenatal care at UCLA Health, plan to deliver at a UCLA hospital, and were diagnosed with gestational diabetes may qualify for this study. Participants will also complete surveys about their experiences months after delivery. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could enhance future diabetes care.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using metformin, steroids, or terbutaline within 4 hours of delivery.

Research has shown that continuous glucose monitors (CGMs) are safe for pregnant women with diabetes. One study found that the Dexcom G7 CGM system was accurate and easy to use, providing reliable blood sugar readings without requiring extra blood tests. This allows real-time monitoring of blood sugar levels without frequent finger pricks.

Another study suggested that CGMs are particularly beneficial for women with gestational diabetes, a type of diabetes that can occur during pregnancy, especially if they experience frequent changes in blood sugar levels. This is crucial for effective blood sugar management by both patients and doctors.

Unlike traditional methods for managing gestational diabetes, which typically involve frequent finger-prick blood tests, the continuous glucose monitor (CGM) offers real-time tracking of blood sugar levels. This device provides a much clearer picture of glucose fluctuations over a 24-hour period without the need for constant manual testing. Researchers are excited about this approach because it could lead to more precise management of blood sugar levels, potentially improving outcomes for both mothers and their babies. Plus, the convenience and reduced discomfort of using a CGM could make managing gestational diabetes less burdensome.

Research has shown that continuous glucose monitoring (CGM) can help people with gestational diabetes control their blood sugar levels more effectively. In one study, 65 pregnant women with Type 2 diabetes and gestational diabetes used CGM and managed their glucose levels more effectively. Another study with 340 women demonstrated that CGM led to more stable blood sugar levels and better overall control. Additionally, using CGM in gestational diabetes has been linked to healthier outcomes for both mothers and their babies, such as lower birth weights and fewer cases of large babies. In this trial, participants will receive a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data. These findings suggest that CGM could be a helpful tool for managing gestational diabetes and its long-term effects.¹²³⁶⁷